AMEX:SLS SLS International Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SLS International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC Filings SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSLS International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, SLS International has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoverageSLS International has received no research coverage in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesSLS International has received 448 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSLS International has received 227 “underperform” votes. (Add your “underperform” vote.)Community SentimentSLS International has received 66.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SLS International and other stocks. Vote “Outperform” if you believe SLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSLS International does not currently pay a dividend.Dividend GrowthSLS International does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SLS International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.76% of the stock of SLS International is held by insiders.Percentage Held by InstitutionsOnly 16.62% of the stock of SLS International is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange AMEX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolAMEX:SLS Previous Symbol CUSIPN/A CIK1390478 Webwww.sls-international.com Phone+1-417-8834549Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable 30 days | 90 days | 365 days | Advanced Chart Receive SLS News and Ratings via Email Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. SLS International (AMEX:SLS) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of SLS International? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SLS International in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SLS International. How were SLS International's earnings last quarter? SLS International Inc (AMEX:SLS) posted its earnings results on Thursday, August, 13th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.02. View SLS International's earnings history. When did SLS International's stock split? How did SLS International's stock split work? SLS International shares reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of SLS International stock prior to the reverse split would have 2 shares after the split. What price target have analysts set for SLS? 1 brokers have issued twelve-month price targets for SLS International's shares. Their forecasts range from $12.00 to $12.00. On average, they expect SLS International's stock price to reach $12.00 in the next year. View analysts' price targets for SLS International. Who are some of SLS International's key competitors? Some companies that are related to SLS International include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux (ACR), Actinogen Medical (ACW), Adalta (1AD), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC) and Arno Therapeutics (ARNI). View all competitors. What other stocks do shareholders of SLS International own? Based on aggregate information from My MarketBeat watchlists, some companies that other SLS International investors own include Unilife (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Sunesis Pharmaceuticals (SNSS), Novavax (NVAX), Athersys (ATHX), Catalyst Pharmaceuticals (CPRX) and Fission Uranium (FCUUF). Who are SLS International's key executives? SLS International's management team includes the following people: Dr. Angelos M. Stergiou M.D., ScD h.c., Founder, Pres, CEO & Director (Age 44, Pay $962.5k)Mr. John Thomas Burns CPA, CPA, VP of Fin. & Corp. Controller & Interim Principal Accounting Officer (Age 35, Pay $338.45k)Ms. Barbara A. Wood, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $525.49k)Mr. Martin G. Baum, Chief Operating Officer (Age 54)Dr. Dragan Cicic, Sr. VP of Clinical Devel. (Age 57) What is SLS International's stock symbol? SLS International trades on the AMEX under the ticker symbol "SLS." How do I buy shares of SLS International? Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SLS International's official website? The official website for SLS International is www.sls-international.com. How can I contact SLS International? SLS International's mailing address is 3119 S Scenic Ave, SPRINGFIELD, MO 65807-3926, United States. The biotechnology company can be reached via phone at +1-417-8834549 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
